This Hyperimmune Globulins market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.
The hyperimmune globulins market size has grown strongly in recent years. It will grow from $1.91 billion in 2024 to $2.06 billion in 2025 at a compound annual growth rate (CAGR) of 7.8%. The growth in the historic period can be attributed to increased government support, rise in healthcare expenditures.
The hyperimmune globulins market size is expected to see strong growth in the next few years. It will grow to $2.76 billion in 2029 at a compound annual growth rate (CAGR) of 7.6%. The growth in the forecast period can be attributed to the increasing prevalence of infectious diseases, growing awareness about the benefits of hyperimmune globulin injections, increasing demand for immunoglobulins, rising prevalence of alpha-1 antitrypsin deficiency, rising incidence of immune deficiencies. Major trends in the forecast period include technological advancements and innovation, investment in research and development, demand for passive immunity treatments, advancements in plasma-derived therapies, and technological advancements in manufacturing.
The hyperimmune globulin market is set to grow due to the increasing prevalence of infectious diseases. These diseases, caused by pathogens such as viruses, bacteria, fungi, and parasites, are on the rise due to factors such as antimicrobial resistance, climate change, and population growth. Hyperimmune globulins play a crucial role in combating infectious diseases by providing immediate passive immunity through concentrated antibodies targeting specific pathogens. This aids in disease prevention or treatment, as seen in cases such as chronic hepatitis B, where the number of cases in the US increased by 17% from 2021 to 2022. Therefore, the growth of infectious diseases is directly impacting the hyperimmune globulin market.
Government efforts to advance healthcare research and development are poised to boost the hyperimmune globulins market in the coming years. These initiatives are escalating due to growing demand for innovative medical solutions and the necessity to confront emerging health issues. They play a crucial role in fostering the development and accessibility of hyperimmune globulins, particularly in combating specific infectious diseases effectively. For example, in 2022, the UK government allocated £260 million (US $270.65 million) through the Business, Energy, and Industrial Strategy (BEIS) and the Department of Health and Social Care (DHSC) to enhance healthcare research and manufacturing. This funding supports NHS-led health research, new privacy-preserving platforms for diagnostics and treatment, clinical research services, and also includes £60 million (US $63.6 million) to bolster life sciences manufacturing in the UK. Therefore, the increasing government focus on healthcare research and development is a key driver of the hyperimmune globulins market.
In April 2022, Grifols S.A., a pharmaceutical company based in Spain, acquired Biotest for an undisclosed sum. This acquisition positions Grifols to enhance and diversify its product portfolio, increase the availability of plasma therapies, operate the largest private European network of plasma centers with 87 centers, and stimulate revenue growth and margin expansion. Biotest, a biotechnology company based in Germany, specializes in hyperimmune globulins, which aligns with Grifols' strategic goals.
Major companies operating in the hyperimmune globulins market are F. Hoffmann-La Roche AG, Bayer AG, Takeda Pharmaceutical Company Limited, Baxter International Inc., CSL Ltd., Fresenius Kabi AG, Grifols SA, Octapharma AG, Shanghai RAAS Blood Products Co. Ltd., Emergent BioSolutions Inc., Kedrion Biopharma Inc., LFB SA, Hualan Biological Engineering Inc., FFF Enterprises Inc., Taibang Biologic Group, Bio Products Laboratory (BPL) Ltd., ADMA Biologics, Cangene Corporation, Kamada Ltd., Saol Therapeutics Inc., Omrix Biopharmaceuticals Ltd., Shire, Sichuan Yuanda Shuyang Pharmaceutical Co. Ltd., BioCare Inc.
North America was the largest region in the hyperimmune globulins market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hyperimmune globulins market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hyperimmune globulins market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Hyperimmune globulins are specialized preparations of antibodies enriched with specific antibodies against a particular pathogen or antigen. These preparations are obtained from the plasma of individuals who have high levels of antibodies against a specific infectious agent or toxin. They are utilized for passive immunization to confer immediate immunity against certain diseases, particularly in situations requiring prompt protection.
The primary types of hyperimmune globulins include hepatitis B hyperimmune globulin, rabies hyperimmune globulin, tetanus hyperimmune globulin, cytomegalovirus (CMV) hyperimmune globulin, varicella-zoster virus (VZV) hyperimmune globulin, respiratory syncytial virus (RSV) hyperimmune globulin, among others. Hepatitis B hyperimmune globulin, for example, is derived from the plasma of donors with high antibody titers against the hepatitis B virus. These preparations are administered via various routes such as intramuscular or intravenous, serving diverse applications across governmental, private, and other sectors.
The hyperImmune globulin market research report is one of a series of new reports that provides hyperImmune globulin market statistics, including hyperImmune globulins industry global market size, regional shares, competitors with a hyperImmune globulin market share, detailed hyperImmune globulin market segments, market trends, and opportunities, and any further data you may need to thrive in the hyperImmune globulins industry. This hyperImmune globulin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The hyperimmune globulins market consists of sales of bayrab, hepaGam B, Tetanus Immune Globulin (TIG), variZIG, respiGam, and cytogam. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The hyperimmune globulins market size has grown strongly in recent years. It will grow from $1.91 billion in 2024 to $2.06 billion in 2025 at a compound annual growth rate (CAGR) of 7.8%. The growth in the historic period can be attributed to increased government support, rise in healthcare expenditures.
The hyperimmune globulins market size is expected to see strong growth in the next few years. It will grow to $2.76 billion in 2029 at a compound annual growth rate (CAGR) of 7.6%. The growth in the forecast period can be attributed to the increasing prevalence of infectious diseases, growing awareness about the benefits of hyperimmune globulin injections, increasing demand for immunoglobulins, rising prevalence of alpha-1 antitrypsin deficiency, rising incidence of immune deficiencies. Major trends in the forecast period include technological advancements and innovation, investment in research and development, demand for passive immunity treatments, advancements in plasma-derived therapies, and technological advancements in manufacturing.
The hyperimmune globulin market is set to grow due to the increasing prevalence of infectious diseases. These diseases, caused by pathogens such as viruses, bacteria, fungi, and parasites, are on the rise due to factors such as antimicrobial resistance, climate change, and population growth. Hyperimmune globulins play a crucial role in combating infectious diseases by providing immediate passive immunity through concentrated antibodies targeting specific pathogens. This aids in disease prevention or treatment, as seen in cases such as chronic hepatitis B, where the number of cases in the US increased by 17% from 2021 to 2022. Therefore, the growth of infectious diseases is directly impacting the hyperimmune globulin market.
Government efforts to advance healthcare research and development are poised to boost the hyperimmune globulins market in the coming years. These initiatives are escalating due to growing demand for innovative medical solutions and the necessity to confront emerging health issues. They play a crucial role in fostering the development and accessibility of hyperimmune globulins, particularly in combating specific infectious diseases effectively. For example, in 2022, the UK government allocated £260 million (US $270.65 million) through the Business, Energy, and Industrial Strategy (BEIS) and the Department of Health and Social Care (DHSC) to enhance healthcare research and manufacturing. This funding supports NHS-led health research, new privacy-preserving platforms for diagnostics and treatment, clinical research services, and also includes £60 million (US $63.6 million) to bolster life sciences manufacturing in the UK. Therefore, the increasing government focus on healthcare research and development is a key driver of the hyperimmune globulins market.
In April 2022, Grifols S.A., a pharmaceutical company based in Spain, acquired Biotest for an undisclosed sum. This acquisition positions Grifols to enhance and diversify its product portfolio, increase the availability of plasma therapies, operate the largest private European network of plasma centers with 87 centers, and stimulate revenue growth and margin expansion. Biotest, a biotechnology company based in Germany, specializes in hyperimmune globulins, which aligns with Grifols' strategic goals.
Major companies operating in the hyperimmune globulins market are F. Hoffmann-La Roche AG, Bayer AG, Takeda Pharmaceutical Company Limited, Baxter International Inc., CSL Ltd., Fresenius Kabi AG, Grifols SA, Octapharma AG, Shanghai RAAS Blood Products Co. Ltd., Emergent BioSolutions Inc., Kedrion Biopharma Inc., LFB SA, Hualan Biological Engineering Inc., FFF Enterprises Inc., Taibang Biologic Group, Bio Products Laboratory (BPL) Ltd., ADMA Biologics, Cangene Corporation, Kamada Ltd., Saol Therapeutics Inc., Omrix Biopharmaceuticals Ltd., Shire, Sichuan Yuanda Shuyang Pharmaceutical Co. Ltd., BioCare Inc.
North America was the largest region in the hyperimmune globulins market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hyperimmune globulins market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hyperimmune globulins market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Hyperimmune globulins are specialized preparations of antibodies enriched with specific antibodies against a particular pathogen or antigen. These preparations are obtained from the plasma of individuals who have high levels of antibodies against a specific infectious agent or toxin. They are utilized for passive immunization to confer immediate immunity against certain diseases, particularly in situations requiring prompt protection.
The primary types of hyperimmune globulins include hepatitis B hyperimmune globulin, rabies hyperimmune globulin, tetanus hyperimmune globulin, cytomegalovirus (CMV) hyperimmune globulin, varicella-zoster virus (VZV) hyperimmune globulin, respiratory syncytial virus (RSV) hyperimmune globulin, among others. Hepatitis B hyperimmune globulin, for example, is derived from the plasma of donors with high antibody titers against the hepatitis B virus. These preparations are administered via various routes such as intramuscular or intravenous, serving diverse applications across governmental, private, and other sectors.
The hyperImmune globulin market research report is one of a series of new reports that provides hyperImmune globulin market statistics, including hyperImmune globulins industry global market size, regional shares, competitors with a hyperImmune globulin market share, detailed hyperImmune globulin market segments, market trends, and opportunities, and any further data you may need to thrive in the hyperImmune globulins industry. This hyperImmune globulin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The hyperimmune globulins market consists of sales of bayrab, hepaGam B, Tetanus Immune Globulin (TIG), variZIG, respiGam, and cytogam. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Hyperimmune Globulins Market Characteristics3. Hyperimmune Globulins Market Trends and Strategies4. Hyperimmune Globulins Market - Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market32. Global Hyperimmune Globulins Market Competitive Benchmarking and Dashboard33. Key Mergers and Acquisitions in the Hyperimmune Globulins Market34. Recent Developments in the Hyperimmune Globulins Market
5. Global Hyperimmune Globulins Growth Analysis and Strategic Analysis Framework
6. Hyperimmune Globulins Market Segmentation
7. Hyperimmune Globulins Market Regional and Country Analysis
8. Asia-Pacific Hyperimmune Globulins Market
9. China Hyperimmune Globulins Market
10. India Hyperimmune Globulins Market
11. Japan Hyperimmune Globulins Market
12. Australia Hyperimmune Globulins Market
13. Indonesia Hyperimmune Globulins Market
14. South Korea Hyperimmune Globulins Market
15. Western Europe Hyperimmune Globulins Market
16. UK Hyperimmune Globulins Market
17. Germany Hyperimmune Globulins Market
18. France Hyperimmune Globulins Market
19. Italy Hyperimmune Globulins Market
20. Spain Hyperimmune Globulins Market
21. Eastern Europe Hyperimmune Globulins Market
22. Russia Hyperimmune Globulins Market
23. North America Hyperimmune Globulins Market
24. USA Hyperimmune Globulins Market
25. Canada Hyperimmune Globulins Market
26. South America Hyperimmune Globulins Market
27. Brazil Hyperimmune Globulins Market
28. Middle East Hyperimmune Globulins Market
29. Africa Hyperimmune Globulins Market
30. Hyperimmune Globulins Market Competitive Landscape and Company Profiles
31. Hyperimmune Globulins Market Other Major and Innovative Companies
35. Hyperimmune Globulins Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Hyperimmune Globulins Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on hyperimmune globulins market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for hyperimmune globulins ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The hyperimmune globulins market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include: the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Type: Hepatitis B Hyperimmune Globulin; Rabies Hyperimmune Globulin; Tetanus Hyperimmune Globulin; Cytomegalovirus (CMV) Hyperimmune Globulin; Varicella-Zoster Virus (VZV) Hyperimmune Globulin; Respiratory Syncytial Virus (RSV) Hyperimmune Globulin; Other Types2) By Route of Administration: Intramuscular; Intravenous
3) By Application: Government Institution; Private Sector; Other Applications
Subsegments:
1) By Hepatitis B Hyperimmune Globulin: Intramuscular Hepatitis B Hyperimmune Globulin; Intravenous Hepatitis B Hyperimmune Globulin2) By Rabies Hyperimmune Globulin: Rabies Immune Globulin (Human); Rabies Immune Globulin (Equine)
3) By Tetanus Hyperimmune Globulin: Tetanus Immune Globulin (Human); Tetanus Immune Globulin (Equine)
4) By Cytomegalovirus (Cmv) Hyperimmune Globulin: Cmv Immune Globulin for Organ Transplantation; Cmv Immune Globulin for Neonatal Infection
5) By Varicella-Zoster Virus (Vzv) Hyperimmune Globulin: Vzv Immune Globulin for Post-Exposure Prophylaxis; Vzv Immune Globulin for Immunocompromised Patients
6) By Respiratory Syncytial Virus (Rsv) Hyperimmune Globulin: Rsv Immune Globulin for Infants and Children; Rsv Immune Globulin for Adults With Respiratory Conditions
7) By Other Types: Diphtheria Hyperimmune Globulin; Botulism Hyperimmune Globulin; Other Specialized Hyperimmune Globulins
Key Companies Mentioned: F. Hoffmann-La Roche AG; Bayer AG; Takeda Pharmaceutical Company Limited; Baxter International Inc.; CSL Ltd.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
The major companies featured in this Hyperimmune Globulins market report include:- F. Hoffmann-La Roche AG
- Bayer AG
- Takeda Pharmaceutical Company Limited
- Baxter International Inc.
- CSL Ltd.
- Fresenius Kabi AG
- Grifols SA
- Octapharma AG
- Shanghai RAAS Blood Products Co. Ltd.
- Emergent BioSolutions Inc.
- Kedrion Biopharma Inc.
- LFB SA
- Hualan Biological Engineering Inc.
- FFF Enterprises Inc.
- Taibang Biologic Group
- Bio Products Laboratory (BPL) Ltd.
- ADMA Biologics
- Cangene Corporation
- Kamada Ltd.
- Saol Therapeutics Inc.
- Omrix Biopharmaceuticals Ltd.
- Shire
- Sichuan Yuanda Shuyang Pharmaceutical Co. Ltd.
- BioCare Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | April 2025 |
| Forecast Period | 2025 - 2029 |
| Estimated Market Value ( USD | $ 2.06 Billion |
| Forecasted Market Value ( USD | $ 2.76 Billion |
| Compound Annual Growth Rate | 7.6% |
| Regions Covered | Global |
| No. of Companies Mentioned | 25 |
